Integrative epidemiology: From risk assessment to outcome prediction

Journal of Clinical Oncology

Volumn 23, Issue 2, 2005, Pages 267-275

  Spitz, Margaret R ^a   Wu, Xifeng ^a   Mills, Gordon ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (METHYLNITROSAMINO) 1 (3 PYRIDYL) 1 BUTANONE; CARCINOGEN; CISPLATIN; CYCLIN D1; CYTOCHROME P450 2A6; GLUTATHIONE; MATRIX METALLOPROTEINASE; NITROSAMINE;

CANCER CHEMOTHERAPY; CANCER GENETICS; CANCER RADIOTHERAPY; CANCER RISK; CANCER SCREENING; CARCINOGENESIS; CELL CYCLE REGULATION; CHEMOPROPHYLAXIS; DETOXIFICATION; DNA POLYMORPHISM; HUMAN; OVARY CARCINOMA; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SMOKING; TREATMENT OUTCOME; DISEASE PREDISPOSITION; ENVIRONMENTAL EXPOSURE; EPIDEMIOLOGY; GENETIC PREDISPOSITION; GENETICS; NEOPLASM; PHARMACOGENETICS; RISK ASSESSMENT;

CARCINOGENS; DISEASE SUSCEPTIBILITY; ENVIRONMENTAL EXPOSURE; EPIDEMIOLOGY, MOLECULAR; GENETIC PREDISPOSITION TO DISEASE; HUMANS; NEOPLASMS; PHARMACOGENETICS; PROGNOSIS; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 13744261017     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.05.122     Document Type: Review

References (86)

1. Ross JS, Ginsburg GS: Integration of molecular diagnostics with therapeutics: implications for drug discovery and patient care. Expert Rev Mol Diagn 2:531-541, 2002
2. Ginsburg GS, McCarthy JJ: Personalized medicine: revolutionizing drug discovery and patient care. Trends Biotechnol 19:491-496, 2001
3. Liotta LA, Kohn EC, Petricoin EF: Clinical proteomics: personalized molecular medicine. JAMA 286:2211-2214, 2001
4. Ross JS, Linette GP, Stec J, et al: Breast cancer biomarkers and molecular medicine: part II. Expert Rev Mol Diagn 4:169-188, 2004
5. Lerman C, Berrettini W: Elucidating the role of genetic factors in smoking behavior and nicotine dependence. Am J Med Genet 118B:48-54, 2003
6. Swan GE, Hudmon KS, Jack LM, et al: Environmental and genetic determinants of tobacco use: Methodology for a multidisciplinary, longitudinal family-based investigation. Cancer Epidemiol Biomarkers Prev 12:994-1005, 2003
7. Xu C, Rao YS, Xu B, et al: An in vivo pilot study characterizing the new CYP2A6*7, *8, and *10 alleles. Biochem Biophys Res Commun 290:318-324, 2002
8. Yoshida R, Nakajima M, Watanabe Y, et al: Genetic polymorphisms in human CYP2A6 gene causing impaired nicotine metabolism. Br J Clin Pharmacol 54:511-517, 2002
9. Oscarson M, McLellan RA, Gullsten H, et al: Identification and characterization of novel polymorphisms in the CYP2A locus: Implications for nicotine metabolism. FEBS Lett 460:321-327, 1999
10. Oscarson M, McLellan RA, Asp V, et al: Characterization of a novel CYP2A7/CYP2A6 hybrid allele (CYP2A6*12) that causes reduced CYP2A6 activity. Hum Mutat 20:275-283, 2002
11. Pitarque M, von Richter O, Oke B, et al: Identification of a single nucleotide polymorphism in the TATA box of the CYP2A6 gene: impairment of its promoter activity. Biochem Biophys Res Commun 284:455-460, 2001
12. Tyndale RF, Pianezza ML, Sellers EM: A common genetic defect in nicotine metabolism decreases dependence and lowers cigarette consumption. Nicotine Tob Res 1:S63-S67, 1999 (1 suppl 2)
13. Pianezza ML, Sellers EM, Tyndale RF: Nicotine metabolism defect reduces smoking. Nature 393:750, 1998
14. Rao Y, Hoffmann E, Zia M, et al: Duplications and defects in the CYP2A6 gene: identification, genotyping, and in vivo effects on smoking. Mol Pharmacol 58:747-755, 2000
15. Gu DF, Hinks LJ, Morton NE, et al: The use of long PCR to confirm three common alleles at the CYP2A6 locus and the relationship between genotype and smoking habit. Ann Hum Genet 64:383-390, 2000
16. Ariyoshi N, Miyamoto M, Umetsu Y, et al: Genetic polymorphism of CYP2A6 gene and tobacco-induced lung cancer risk in male smokers. Cancer Epidemiol Biomarkers Prev 11:890-894, 2002
17. Sellers EM, Kaplan HL, Tyndale RF: Inhibition of cytochrome P450 2A6 increases nicotine's oral bioavailability and decreases smoking. Clin Pharmacol Ther 68:35-43, 2000
18. Oscarson M: Genetic polymorphisms in the cytochrome P450 2A6 (CYP2A6) gene: implications for interindividual differences in nicotine metabolism. Drug Metab Dispos 29:91-95, 2001
19. Miyamoto M, Umetsu Y, Dosaka-Akita H, et al: CYP2A6 gene deletion reduces susceptibility to lung cancer. Biochem Biophys Res Commun 261:658-660, 1999
20. Loriot MA, Rebuissou S, Oscarson M, et al: Genetic polymorphisms of cytochrome P450 2A6 in a case-control study on lung cancer in a French population. Pharmacogenetics 11:39-44, 2001
21. Tsukino H, Kuroda Y, Qiu D, et al: Effects of cytochrome P450 (CYP) 2A6 gene deletion and CYP2E1 genotypes on gastric adenocarcinoma. Int J Cancer 100:425-428, 2002
22. Topcu Z, Chiba I, Fujieda M, et al: CYP2A6 gene deletion reduces oral cancer risk in betel quid chewers in Sri Lanka. Carcinogenesis 23:595-598, 2002
23. Tyndale R, Sellers EM: Variable CYP2A6-mediated nicotine metabolism alters smoking behavior and risk. Drug Metab Dispos 29:548-552, 2001
24. Takeuchi H, Saoo K, Yokohira M, et al: Pretreatment with 8-methoxypsoralen, a potent human CYP2A6 inhibitor, strongly inhibits lung tumorigenesis induced by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in female A/J mice. Cancer Res 63:7581-7583, 2003
25. Strange RC, Spiteri MA, Ramachandran S, et al: Glutathione-S-transferase family of enzymes. Mutat Res 482:21-26, 2001
26. Seidegard J, Ekstrom G: The role of human glutathione transferases and epoxide hydrolases in the metabolism of xenobiotics. Environ Health Perspect 105:791-799, 1997
27. Houlston RS: Glutathione S-transferase M1 status and lung cancer risk: A meta-analysis. Cancer Epidemiol Biomarkers Prev 8:675-682, 1999
28. Rebbeck TR: Molecular epidemiology of the human glutathione S-transferase genotypes GSTM1 and GSTT1 in cancer susceptibility. Cancer Epidemiol Biomarkers Prev 6:733-743, 1997
29. Hirvonen A, Nylund L, Kociba P, et al: Modulation of urinary mutagenicity by genetically determined carcinogen metabolism in smokers. Carcinogenesis 15:813-815, 1994
30. el-Zein R, Zwischenberger JB, Wood TG, et al: Combined genetic polymorphism and risk for development of lung cancer. Mutat Res 381:189-200, 1997
31. Spitz MR, Duphorne CM, Detry MA, et al: Dietary intake of isothiocyanates: Evidence of a joint effect with glutathione S-transferase polymorphisms in lung cancer risk. Cancer Epidemiol Biomarkers Prev 9:1017-1020, 2000
32. Deakin M, Elder J, Hendrickse C, et al: Glutathione S-transferase GSTT1 genotypes and susceptibility to cancer: studies of interactions with GSTM1 in lung, oral, gastric and colorectal cancers. Carcinogenesis 17:881-884, 1996
33. To-Figueras J, Gene M, Gomez-Catalan J, et al: Glutathione S-transferase M1 (GSTM1) and T1 (GSTT1) polymorphisms and lung cancer risk among Northwestern Mediterraneans. Carcinogenesis 18:1529-1533, 1997
34. Stucker I, Hirvonen A, de Waziers I, et al: Genetic polymorphisms of glutathione S-transferases as modulators of lung cancer susceptibility. Carcinogenesis 23:1475-1481, 2002
35. Anttila S, Hirvonen A, Vainio H, et al: Immunohistochemical localization of glutathione S-transferases in human lung cancer. Cancer Res 53:5643-5648, 1993
36. Watson MA, Stewart RK, Smith GBJ, et al: Human glutathione S-transferase P1 polymorphisms: Relationship to lung tissue enzyme activity and population frequency distribution. Carcinogenesis 19:275-280, 1998
37. Ryberg D, Skaug V, Hewer A, et al: Genotypes of glutathione transferase M1 and P1 and their significance for lung DNA adduct levels and cancer risk. Carcinogenesis 18:1285-1289, 1997
38. Wang Y, Spitz MR, Schabath MB, et al: Association between glutathione S-transferase p1 polymorphism and lung cancer risk in Caucasians: A case-control study. Lung Cancer 40:25-32, 2003
39. Miller DP, de Vivo I, Neuberg D, et al: Association between self-reported environmental tobacco smoke exposure and lung cancer: modification by GSTP1 polymorphism. Int J Cancer 104:758-763, 2003
40. Shiga H, Heath EI, Rasmussen AA, et al: Prognostic value of p53, glutathione S-transferase pi, and thymidylate synthase for neoadjuvant cisplatin-based chemotherapy in head and neck cancer. Clin Cancer Res 5:4097-4104, 1999
41. Mistry P, Kelland LR, Abel G, et al: The relationships between glutathione, glutathione-S-transferase and cytotoxicity of platinum drugs and melphalan in eight human ovarian carcinoma cell lines. Br J Cancer 64:215-220, 1991
42. Nakanishi Y, Matsuki H, Takayama K, et al: Glutathione derivatives enhance Adriamycin cytotoxicity in a human adenocarcinoma cell line. Anticancer Res 17:2129-2134, 1997
43. Inoue T, Ishida T, Sugio K, et al: Glutathione-S-transferase Pi is a powerful indicator in chemotherapy of human lung squamous-cell carcinoma. Respiration 62:223-227, 1995
44. Yang P, Yokomizo A, Tazelaar HD, et al: Genetic determinants of lung cancer short-term survival: the role of glutathione-related genes. Lung Cancer 35:221-229, 2002
45. Medeiros R, Pereira D, Afonso N, et al: Platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma: glutathione S-transferase genetic polymorphisms as predictive biomarkers of disease outcome. Int J Clin Oncol 8:156-161, 2003
46. Kelsey KT, Hankinson SE, Colditz GA, et al: Glutathione S-transferase class mu deletion polymorphism and breast cancer: results from prevalent versus incident cases. Cancer Epidemiol Biomarkers Prev 6:511-515, 1997
47. Ambrosone CB, Sweeney C, Coles BF, et al: Polymorphisms in glutathione S-transferases (GSTM 1 and GSTT1) and survival after treatment for breast cancer. Cancer Res 61:7130-7135, 2001
48. Dasgupta RK, Adamson PJ, Davies FE, et al: Polymorphic variation in GSTP1 modulates outcome following therapy for multiple myeloma. Blood 102:2345-2350, 2003
49. Stoehlmacher J, Park DJ, Zhang W, et al: Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer. J Natl Cancer Inst 94:936-942, 2002
50. Davies SM, Bhatia S, Ross JA, et al: Glutathione S-transferase genotypes, genetic susceptibility, and outcome of therapy in childhood acute lymphoblastic leukemia. Blood 100:67-71, 2002
51. Sweeney C, Nazar-Stewart V, Stapelton PL, et al: Glutathione S-transferase M1, T1, and P1 polymorphisms and survival among lung cancer patients. Cancer Epidemiol Biomarkers Prev 12:527-533, 2003
52. Betticher DC, Thatcher N, Altermatt HJ, et al: Alternate splicing produces a novel cyclin D1 transcript. Oncogene 11:1005-1011, 1995
53. Kong S, Amos CI, Luthra R, et al: Effects of cyclin D1 polymorphism on age of onset of hereditary nonpolyposis colorectal cancer. Cancer Res 60:249-252, 2000
54. Kong S, Wei Q, Amos CI, et al: Cyclin D1 polymorphism and increased risk of colorectal cancer at young age. J Natl Cancer Inst 93:1106-1108, 2001
55. Qiuling S, Yuxin Z, Suhua Z, et al: Cyclin D1 gene polymorphism and susceptibility to lung cancer in a Chinese population. Carcinogenesis 24:1499-1503, 2003
56. Wang L, Habuchi T, Takahashi T, et al: Cyclin D1 gene polymorphism is associated with an increased risk of urinary bladder cancer. Carcinogenesis 23:257-264, 2002
57. Zheng Y, Shen H, Sturgis EM, et al: Cyclin D1 polymorphism and risk for squamous cell carcinoma of the head and neck: a case-control study. Carcinogenesis 22:1195-1199, 2001
58. Betticher DC, Heighway J, Hasleton PS, et al: Prognostic significance of CCND1 (cyclin D1) overexpression in primary resected non-small-cell lung cancer. Br J Cancer 73:294-300, 1996
59. Nishio M, Koshikawa T, Yatabe Y, et al: Prognostic significance of cyclin D1 and retinoblastoma expression in combination with p53 abnormalities in primary, resected non-small cell lung cancers. Clin Cancer Res 3:1051-1058, 1997
60. Feakins RM, Nichols CD, Bidd H, et al: Abnormal expression of pRb, p16, and cyclin D1 in gastric adenocarcinoma and its lymph node metastases: relationship with pathological features and survival. Hum Pathol 34:1276-1282, 2003
61. Bae DS, Cho SB, Kim YJ, et al: Aberrant expression of cyclin D1 is associated with poor prognosis in early stage cervical cancer of the uterus. Gynecol Oncol 81:341-347, 2001
62. Ikehara M, Oshita F, Ito H, et al: Expression of cyclin D1 but not of cyclin E is an indicator of poor prognosis in small adenocarcinoma of the lung. Oncol Rep 10:137-139, 2003
63. Hui AM, Shi YZ, Takayama T, et al: Cyclin D1 overexpression is a critical event in gallbladder carcinogenesis and independently predicts decreased survival for patients with gallbladder carcinoma. Clin Cancer Res 6:4272-4277, 2000
64. Matthias C, Branigan K, Jahnke V, et al: Polymorphisms within the cyclin D1 gene is associated with prognosis in patients with squamous cell carcinoma of the head and neck. Clin Cancer Res 4:2411-2418, 1998
65. Matthias C, Jahnke V, Jones PW, et al: Cyclin D1, glutathione S-transferase, and cytochrome P450 genotypes and outcome in patients with upper aerodigestive tract cancers: Assessment of the importance of individual genes using multivariate analysis. Cancer Epidemiol Biomarkers Prev 8:815-823, 1999
66. Egeblad M, Werb Z: New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2:161-174, 2002
67. Jones JL, Glynn P, Walker RA: Expression of MMP-2 and MMP-9, their inhibitors, and the activator MT1-MMP in primary breast carcinomas. J Pathol 189:161-168, 1999
68. Tlsty TD: Cell-adhesion-dependent influences on genomic instability and carcinogenesis. Curr Opin Cell Biol 10:647-653, 1998
69. Mercer BA, Kolesnikova N, Sonett J, et al: Extracellular regulated kinase/mitogen activated protein kinase is up-regulated in pulmonary emphysema and mediates matrix metalloproteinase-1 induction by cigarette smoke. J Biol Chem 279:17690-17696, 2004
70. Buttice G, Duterque-Coquillaud M, Basuyaux JP, et al: Erg, an Ets-family member, differentially regulates human collagenase1 (MMP1) and stromelysim (MMP3) gene expression by physically interacting with the Fos/Jun complex. Oncogene 13:2297-2306, 1996
71. Rutter JL, Mitchell TI, Buttice G, et al: A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter creates an Ets binding site and augments transcription. Cancer Res 58:5321-5325, 1998
72. Kanamori Y, Matsushima M, Minaguchi T, et al: Correlation between expression of the matrix metalloproteinase-1 gene in ovarian cancer and an insertion/deletion polymorphism in its promoter region. Cancer Res 59:4225-4227, 1999
73. Zhu Y, Spitz MR, Lei L, et al: A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter enhances lung cancer susceptibility. Cancer Res 61:7825-7829, 2001
74. Miao C, Yu C, Tam W, et al: A functional polymorphism in the matrix metalloproteinase-2 gene promoter (-1306C/T) is associated with risk of development but not metastasis of gastric adenocarcinoma. Cancer Res 63:3987-3990, 2003
75. Yu C, Pan K, Xing D, et al: Correlation between a single nucleotide polymorphism in the matrix metalloproteinase-2 promoter and risk of lung cancer. Cancer Res 62:6430-6433, 2002
76. Huang S, Van Arsdall M, Tedjarati S, et al: Contributions of stromal metalloproteinase-9 to angiogenesis and growth of human ovarian carcinoma in mice. J Natl Cancer Inst 94:1134-1142, 2002
77. Pyke C, Ralfkiaer E, Tryggvason K, et al: Messenger RNA for two type IV collagenases is located in stromal cells in human colon cancer. Am J Pathol 142:359-365, 1993
78. Chambers AF, Matrisian LM: Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 89:1260-1270, 1997
79. Murray GI, Duncan ME, O'Neil P, et al: Matrix metalloproteinases-1 is associated with poor prognosis in colorectal cancer. Nat Med 2:461-462, 1996
80. Murray GI, Duncan ME, O'Neil P, et al: Matrix metalloproteinases-1 is associated with poor prognosis in oesophageal cancer. J Pathol 185:256-261, 1998
81. Werner JA, Rathcke IO, Mandic R: The role of matrix metalloproteinases in squamous cell carcinomas of the head and neck. Clin Exp Metastasis 19:275-282, 2002
82. Katayama A, Bandoh N, Kishibe K, et al: Expressions of matrix metalloproteinases in early-stage oral squamous cell carcinoma as predictive indicators for tumor metastases and prognosis. Clin Cancer Res 10:634-640, 2004
83. Wang M, Wang T, Liu S, et al: The expression of matrix metalloproteinase-2 and -9 in human gliomas of different pathological grades. Brain Tumor Pathol 20:65-72, 2003
84. Toyooka S, Maruyama R, Toyooka KO, et al: Smoke exposure, histologic type and geography-related differences in the methylation profiles of non-small cell lung cancer. Int J Cancer 103:153-160, 2003
85. Frazier ML, Xi L, Zong J, et al: Association of the CpG island methylator phenotype with family history of cancer in patients with colorectal cancer. Cancer Res 63:4805-4808, 2003
86. Harden SV, Tokumaru Y, Westra WH, et al: Gene promoter hypermethylation in tumors and lymph nodes of stage I lung cancer patients. Clin Cancer Res 9:1370-1375, 2003